IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This is a prospective, open label, multi-centre phase II trial with a two-arm non comparative
design aiming to evaluate the safety and efficacy of Enasidenib (investigational product) as
prophylactic consolidation in patients with IDH2-mutated MDS, CMML and AML in remission after
allo-SCT and as salvage therapy in patients with IDH2-mutated MDS, CMML and AML who have
relapsed after allo-SCT.
Phase:
Phase 2
Details
Lead Sponsor:
Heinrich-Heine University, Duesseldorf
Collaborators:
Celgene Corporation Koordinierungszentrum für Klinische Studien Düsseldorf